http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. (HealthDay)—Sofosbuvir seems to be a promising treatment option for patients with chronic hepatitis C virus (HCV) infection, according to two studies published online April 23 in the New England Journal of Medicine to coincide with presentation at The International Liver Congress, the annual meeting of the European Association for the Study of the Liver, held from April 24 to 28 in Amsterdam. http://medicalxpress.com/news/2013-04-sofosbuvir-chronic-hepatitis-infection.html Diseases, Conditions, Syndromes Tue, 23 Apr 2013 13:10:04 EST news285940342 (HealthDay)—For untreated patients with hepatitis C virus (HCV), treatment with an oral nucleotide inhibitor of HCV polymerase, sofosbuvir, plus ribavirin seems effective for genotypes 1, 2, and 3; and the HCV NS3 protease inhibitor ABT-450, combined with low-dose ritonavir (ABT-450/r) plus the nonnucleoside NS5B polymerase inhibitor ABT-333 and ribavirin, seems effective for genotype 1, according to two studies published in the Jan. 2 issue of the New England Journal of Medicine. http://medicalxpress.com/news/2013-01-interferon-free-therapies-hep-virus.html Diseases, Conditions, Syndromes Thu, 03 Jan 2013 11:00:01 EST news276431532 A recent clinical trial found that the adult antiviral drug, tenofovir disoproxil fumarate (tenofovir DF), is safe and effective in treating adolescents with hepatitis B virus (HBV). Trial results published in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases (AASLD), show that tenofovir DF suppressed HBV in 89% of pediatric participants. http://medicalxpress.com/news/2012-12-adult-antiviral-drug-effective-suppressing.html Diseases, Conditions, Syndromes Wed, 05 Dec 2012 11:18:35 EST news273928704 For many patients with the hepatitis C virus (HCV), direct antiviral agents (DAA) offer a potential cure for the disease. The Food and Drug Administration (FDA) has recently approved two new DAAs, telaprevir and boceprevir, and with that clinicians must now decide who should be the first to receive this treatment. Discussion of this timely topic is now available in the June issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases. http://medicalxpress.com/news/2011-05-antiviral-agent-therapy-hepatitis-debate.html Diseases, Conditions, Syndromes Wed, 25 May 2011 10:47:25 EST news225539226